---
title: "Lysergide (DT120) in Generalized anxiety disorder: Care management intervention strategies"
description: "Formulary evidence on Lysergide (DT120, MM120) in Generalized anxiety disorder: Care management intervention strategies. Topics: Stepped care for GAD: NICE, Monitoring of drug treatment: NICE, Collaborative care in primary care: the CALM trial, Collaborative care for anxiety: Cochrane review, and 2 further topics. 6 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description/care-management-intervention-strategies"
published: "2026-11-18T10:42:08-05:00"
modified: "2026-11-18T10:42:08-05:00"
---

# Lysergide (DT120) in Generalized anxiety disorder: Care management intervention strategies

<a id="heading-2.2.2.4"></a>

## 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

### Stepped care for GAD: NICE

> “Follow the stepped-care model, offering the least intrusive, most effective intervention first.”
> “STEP 1: All known and suspected presentations of GAD”
> “Identification and assessment; education about GAD and treatment options; active monitoring”
> “STEP 2: Diagnosed GAD that has not improved after education and active monitoring in primary care”
> “Low-intensity psychological interventions: individual non-facilitated self-help, individual guided self-help and psychoeducational groups”
> “STEP 3: GAD with an inadequate response to step 2 interventions or marked functional impairment”
> “Choice of a high-intensity psychological intervention (cognitive behavioural therapy [CBT]/applied relaxation) or a drug treatment”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.4-2"></a>

### Monitoring of drug treatment: NICE

> “Review the effectiveness and side effects of the drug every 2 to 4 weeks during the first 3 months of treatment and every 3 months thereafter.”
> “If the drug is effective, advise the person to continue taking it for at least a year as the likelihood of relapse is high.”
> “Develop a comprehensive care plan in collaboration with the person with GAD that addresses needs, risks and functional impairment and has a clear treatment plan.”

Source: [NICE clinical guideline CG113 (2011)](https://www.nice.org.uk/guidance/cg113/chapter/Recommendations)

<a id="topic-2.2.2.4-3"></a>

### Collaborative care in primary care: the CALM trial

> “Between June 2006 and April 2008, 1004 primary care patients with PD, GAD, SAD, and/or PTSD were enrolled in the CALM study.”
> “CALM allowed choice of cognitive behavioral therapy (CBT), medication, or both; included real-time web-based outcomes monitoring to optimize treatment decisions and a computer-assisted program to optimize delivery of CBT by non-expert care managers who also assisted primary care providers in promoting adherence and optimizing medications.”
> “At 12 months, response and remission rates (CALM vs. UC) were 63.66% (58.95–68.37) vs. 44.68% (39.76–49.59), and 51.49% (46.60–56.38) vs. 33.28% (28.62–37.93), with a number needed to treat (NNT) of 5.27 (4.18–7.13) for response and 5.5 (4.32–7.55) for remission.”

Source: [Roy-Byrne et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2928714/)

<a id="topic-2.2.2.4-4"></a>

### Collaborative care for anxiety: Cochrane review

> “The results also demonstrated significantly greater improvement in anxiety outcomes for adults with anxiety treated with the collaborative care model in the short‐term (SMD ‐0.30, 95% CI ‐0.44 to ‐0.17; RR 1.50, 95% CI 1.21 to 1.87), medium‐term (SMD ‐0.33, 95% CI ‐0.47 to ‐0.19; RR 1.41, 95% CI 1.18 to 1.69), and long‐term (SMD ‐0.20, 95% CI ‐0.34 to ‐0.06; RR 1.26, 95% CI 1.11 to 1.42).”
> “Collaborative care is associated with significant improvement in depression and anxiety outcomes compared with usual care, and represents a useful addition to clinical pathways for adult patients with depression and anxiety.”

Source: [Archer et al. (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11627142/)

<a id="topic-2.2.2.4-5"></a>

### Symptom-triggered retreatment after a single dose in the DT120 phase 3 trials

> “Open-label treatment in Part B was based on prespecified symptom severity, which allowed for assessment of retreatment patterns and durability of response in a real-world fashion (Figure 2)”
> “To maintain data integrity, participants who met retreatment thresholds and had no safety concerns were required to re-treat”
> “ePRO score ≥10 may prompt unscheduled central assessment”
> “HAM-A ≥16 or MADRS ≥20”

Source: [Jacobsen et al. (2026)](https://definiumtx.com/wp-content/uploads/2026/11/DEF26021035G_Psych-Congress-2026-Methods-Clinical-Trial-DN-Poster_11Sept2026_For-Print.pdf)

<a id="topic-2.2.2.4-6"></a>

### Patient, provider, and site support planned by the company

> “Referral & Treatment Coordination”
> “Treatment-Day Logistics”
> “INTEGRATED COMMERCIAL SUPPORT MODEL”
> “Connecting patients, providers and sites of care”

Source: [Definium Therapeutics corporate presentation (2026)](https://d1io3yog0oux5.cloudfront.net/_b2fa8bdbb960338bfb3dd73de29d58aa/mindmed/db/2394/23570/pdf/Definium_Corporate_Presentation_%28November_2026%29.pdf)

## Related pages
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Terms and abbreviations](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/terms-and-abbreviations.md)
- [Lysergide (DT120): Generalized anxiety disorder](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/executive-summary.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Product information and disease description](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/product-information-and-disease-description.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Clinical evidence](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/clinical-evidence.md)
- [Lysergide (DT120) in Generalized anxiety disorder: Economic information and modeling report](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/economics.md)
- [Lysergide (DT120) in Generalized anxiety disorder: References](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references) · [Markdown](https://www.evicenter.com/drugs/lysergide--generalized-anxiety-disorder/references.md)
